In hypoxic tumors, effector T lymphocytes are not only reduced in their migration from the circulation into the tumor but also weaken in their anti-tumor activity [51,52]; NK activity against cancer cells is also low due to the decreased expression of several activating receptors, including NKG2D, NKp30, and NKp46 [53]. The gene discussed is NCR1; the disease is cancer.